Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silo Pharma (SILO) Cash from Financing Activities (2019 - 2025)

Silo Pharma's Cash from Financing Activities history spans 6 years, with the latest figure at $634922.0 for Q3 2025.

  • For Q3 2025, Cash from Financing Activities fell 63.54% year-over-year to $634922.0; the TTM value through Sep 2025 reached $4.0 million, up 31.01%, while the annual FY2024 figure was $3.2 million, 788.07% up from the prior year.
  • Cash from Financing Activities for Q3 2025 was $634922.0 at Silo Pharma, down from $1.7 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $3.8 million in Q1 2021 and bottomed at -$194423.0 in Q4 2023.
  • The 4-year median for Cash from Financing Activities is $316278.0 (2021), against an average of $916311.2.
  • The largest YoY upside for Cash from Financing Activities was 25209.79% in 2021 against a maximum downside of 100.11% in 2021.
  • A 4-year view of Cash from Financing Activities shows it stood at -$2366.0 in 2021, then tumbled by 8117.37% to -$194423.0 in 2023, then soared by 995.74% to $1.7 million in 2024, then tumbled by 63.54% to $634922.0 in 2025.
  • Per Business Quant, the three most recent readings for SILO's Cash from Financing Activities are $634922.0 (Q3 2025), $1.7 million (Q3 2024), and $1.6 million (Q2 2024).